		Q1-3/2009	Q1-3/2008	Change

Sales	Million EUR	77.8	51.5	51%

Return on revenue before tax (operational)	%	13%	11%	15%

EBITDA	Million EUR	16.1 2	1.1	not comparable
EBIT	Million EUR	10.8	14.9	not comparable

EBT	Million EUR	9.8	14.3	not comparable

EBT (operational)	Million EUR	9.8	5.6	74%

Net income/loss before other shareholders' interests	Million EUR	8.0	9.3	not comparable
Profit	Million EUR	5.3	11.0	not comparable

Earnings per share (basic)	EUR	1.44	3.51	not comparable

Earnings per share (operational, basic)	EUR	1.44	0.94	54%

Operational cash flow	Million EUR	12.0	0.8	>100%
Depreciation and amortization on non-current assets	Million EUR	5.3	6.1	-14%

Staff as of September 30	Persons	519	419 2	4%

Cover page:

The awarding of the EANM Eckert & Ziegler Abstract Award to five aspiring young scientists on the occasion of the annual congress of the European Association of Nuclear Medicine (EANM) in Barcelona.

The 100th MultiSource® Co-60 HDR (High Dose Rate) cancer irradiation device was supplied to Thailand.

Disclaimer:

The official version of this quarterly report is in German. The English translation is provided as a convenience to our shareholders. While we strive to provide an accurate and readable version of our quarterly report in English, the technical nature of a quarterly report often yields awkward phrases and sentences. We understand this can cause confusion. So, please always refer to the German quarterly report for the authoritative version.

Business development of the Eckert & Ziegler Group

Revenue growth

In the first nine months of 2009, the Eckert & Ziegler Group set new records with sales of EUR 78 million and Group profits of EUR 5.3 million, thus far exceeding the existing operative records. Compared with last year's period, sales increased by EUR 26 million, or 51%. Compared with the same nine-month period in the previous year, the profit after tax and minority interests increased by EUR 2.4 million, or 79%, if the special effect resulting from the IBt consolidation in that period is excluded. The profit per share for the three quarters of 2009 taken together equals EUR 1.44.

This enormous success is based on the very positive figures from all three operative segments. Sales in the therapy segment have increased by 26%, or approx. EUR 5 million. The drivers of growth were above all the tumor irradiation equipment, sales of which increased by 55%, or about EUR 2 million, due in particular to increased sales to eastern Europe. The first sales from the Russian project amounting to about EUR 3 million were already included in the second quarter of 2009. International Brachytherapy s.a. (IBt), an associated company of Eckert & Ziegler, had in the first half of the year set up a joint venture with a Russian state fund corporation to manufacture prostate cancer implants in Russia, and had begun supplying plant and equipment.

In the Nuclear Medicine and Industry segment, sales have almost doubled from EUR 22.2 million to EUR 39.6 million. This resulted from the combined effects of including the Nuclitec sales, the increased sales of robust drill hole sources, and a USD exchange rate improvement of 6%.

Despite the loss of sales in Italy, the Radiopharmaceuticals segment grew by 38%. The two main product categories, Modular-Lab and diagnostics for positron emission tomography (PET), continued their uninterrupted growth trend from the previous quarters. Added to this were Nuclitec's aurigamedical sales.

Earnings position

The Therapy segment is turning into an earnings machine. Last year's restructuring costs had a detrimental effect, resulting in only a very modest profit. Now, however, this highly profitable operational business is making a decisive contribution to increasing Group profits. In addition, the start-up of the Russian project already provided additional profits in the second quarter.

The Nuclear Medicine and Industry segment was still the main sources of revenues, just as in previous periods. Sales have increased by 79%. Approximately a third of that, i.e. 25% growth, can be seen in profits after tax and minority interests, which have increased by EUR 0.9 million compared with the same period last year and which now stand at EUR 4.3 million. The results also show that Nuclitec had been integrated successfully and was likewise turning in profits.

The Radiopharmaceuticals segment continues to make a profit despite high launch costs for introducing new products. Gains from the deconsolidation of the Italian stake further increased profits.

The Other segment includes the costs of the holding company which was faced with high lawyer fees in connection with the IBt lawsuit during the current financial year.

The brief segment statistics on the following page (in thousands of euros) illustrate the sources of turnover and profit.

Liquidity

The superlative key figure of the first nine months of 2009 is the operative cash flow of EUR 12.0 million, which also sets a new record. Although earnings for the period declined compared to the previous quarters, the operating cash flow continued to increase, and amounts to EUR 5.5 million in the third quarter of 2009 alone.

External turnover (in TEUR)

Therapy Nuclear Radio- Other Total (IBt) Medicine and pharma-Industry ceuticals External turnover Q1-3/2008 18,916 22,164 10,374 0 51,454 Q1-3/2009 23,877 39,631 14,319 0 77,827 Profit after tax Q1-3/2008 477 3,672 -634 35 3,550 Q1-3/2009 4,038 4,492 148 -660 8,018 Net profit ratio in % Q1-3/2008 3% 17% -6% 7% Q1-3/2009 17% 11% 1% 10% Turnover growth absolute +4,961 +17,467 +3,945 +26,373 in % +26% +79% +38% +51% Profit growth absolute +3,561 +820 +782 +4,468 in % +747% +22% +126%

As each segment has different minority interests, profit after tax was used as a reference. The figures for 2008 have been adjusted to compensate for the special effects of the IBt consolidation.

A comparison with the first three quarters of 2008 is not very informative because in the comparison period the non-cash effects were dominant, but only a slight operational cash inflow was posted. This is in stark contrast to 2009, where the cash flow from business activities is above the profit figure for the period, which itself is very high.

The main reason for this success lies in the fact that, despite the huge increase in sales, receivables were able to be reduced once the payment of the first Russian project turnover, which was only made in October, is disregarded. Inventories were also able to be reduced. Only the reduction of accounts payable led to liquidity outflows.

The investments of EUR 8.2 million for the Nuclitec shares, less the cash reserves, and in property, plant and equipment were largely financed by the capital increase and by taking out loans totaling EUR 5.1 million. This means that the cash gain from the operative capital flow of EUR 12.0 million was reduced by a total of EUR 3.1 million from investments and financing. The dividend payment of EUR 1.1 million is also to be deducted, as well as the change due to the purchase/issue of EUR 0.2 million own shares. Overall, the cash reserves increased by EUR 7.5 million to EUR 14.8 million on September 30, 2009.

Research and development

Work in the Therapy segment concentrated on the development of a complete plant for the production of prostate cancer implants for Russia. The specification was finalized for most of the plant's modules, and the actual development phase was begun.

The range of accessories for the cancer irradiation devices was expanded with improved applicators for use in treating breast cancer and new Fletcher applicators for use in gynecology.

In the Radiopharmaceuticals and the Nuclear Medicine and Industry segments, the focus was on the ongoing further development of existing product lines.

Staff

As of September 30, 2009, the Eckert & Ziegler Group had 348 employees in Germany, and a total of 519 employees worldwide. Compared with the end of 2008, the number of staff increased by 110 (December 31, 2008: 409). This increase is mainly due to the inclusion of the Nuclitec companies.

Outlook

The sales target for the 2009 financial year is EUR 100 million. The Executive Board is maintaining its profits forecast of EUR 6.6 million (EUR 1.80 per share), although this figure does not include any special effects of the whole or partial reversal of provisions in connection with the legal dispute regarding IBt (EUR 7.1 million).

Profit after tax (in TEUR)

3/2009

Milestones

■ The 628,633 shares from the increase in capital decided upon in January 2009 were authorized for trading in the regulated market (Prime Standard) of the Frankfurt stock exchange.

■ International Brachytherapy S.A. (IBt), an associated company of Eckert & Ziegler AG, has supplied the 100th MultiSource® Co-60 HDR (High Dose Rate) cancer irradiation device. The Vajira Hospital in Bangkok, Thailand will use it principally to treat tumors of the uterus, breast and esophagus.

■ Eckert & Ziegler awarded the EANM Eckert & Ziegler Abstract Award to five nuclear medicine researchers for their outstanding scientific work. The award ceremony took place at the annual congress of the European Association of Nuclear Medicine in Barcelona.

Photos (from top to bottom):

MultiSource® applicator for brachytherapy treatment of gynecologic tumors.

The Vajira Hospital in Bangkok will use the MultiSource® cancer irradiation device principally to treat tumors of the uterus, breast and esophagus.

This year's EANM Eckert & Ziegler Abstract Award was awarded to nuclear medicine researchers for their outstanding work in the fields of cancer diagnostics and therapies.

	Quarterly Report	Quarterly Report	9-monthly Report	9-monthly Report
	III/2009	III/2008
	07-09/2009	07-09/2008	01-09/2009	01-09/2008
	TEUR	TEUR	TEUR	TEUR
Net sales	25,474	18,640	77,827	51,454
Cost of sales	-12,710	-10,835	-37,454	-29,305
Gross profit on sales	12,764	7,805	40,373 22	,149
Selling expenses	-4,075	-3,532	-14,023	-9,976
General and administrative expenses	-4,975	-3,446	-14,484	-9,871
Research and non-capitalized development expenses	-782	-1,337	-1,725	-3,409
Other operating income	205	1,235	878	2,631
Other operating expenses	-29	-643	-256	-729
Profit from operations	3,108	82	10,763	795
Other financial items	-137	352	56	14,142
Earnings before interest and taxes (EBIT)	2,971	434	10,819	14,937

Interest received	10	55	40	97
Interest paid	-345	-198	-1,068	-702
Profit before tax	2,636	291	9,791	14,332
Income tax expense	-429	-824	-1,773	-5,003
Profit from continuing operations	2,207	-533	8,018	9,329
Profit from discontinued operations, net	-	-	97	-
Net income	2,207	-533	8,115	9,329

Profit/loss attributable to minority interests	-853	2,184	-2,796	1,698
Dividend to shareholders of Eckert & Ziegler AG	1,354	1,651	5,319	11,027
Earnings per share
Basic	0.36	0.53	1.44	3.51
Diluted	0.36	0.52	1.44	3.49
Average number of shares in circulation (basic)	3,751	3,143	3,686	3,143
Average number of shares in circulation (diluted)	3,771	3,161	3,700	3,161

	9-monthly Report	9-monthly Report
	01-09/2009	01-09/2008
	TEUR	TEUR

Cash flows from operating activities:
Profit for the period	8,116	9,329
Adjustments for:
Depreciation and amortization	5,268	6,132
Proceeds from grants less release of deferred income from grants	45	-403
Deferred tax	-410	2,655
Unrealized foreign currency gains/losses	-51	-841
Long-term provisions, other non-current liabilities	394	-1,002
Gains/losses on the sale of consolidated companies	-	-13,985
Gains/losses on the disposal of non-current assets	49	-
Gains/losses on the sale of securities	-	-77
Other	-54	33
Changes in current assets and liabilities:
Receivables	-487	-456
Inventories	613	-535
Prepaid expenses, other current assets	-176	-287
Trade accounts payable and accounts payable to related parties	-1,680	-562
Income tax liabilities	-1,174	486
Other liabilities	1,525	351
Cash inflows generated from operating activities	11,978	838

Cash flows from investment activities:
Purchase/sale of non-current assets	-4,007	-5,714
Acquisition of consolidated companies	-4,320	2,179
Purchase/sale of shareholdings	28	40
Purchase/sale of securities	101	690
Cash inflows/outflows from investment activities	-8,198	-2,805
Cash flows from financing activities:
Dividends paid	-1,132	-786
Cash inflow from capital increase	2,959	-
Change in long-term borrowings	5,427	3,758
Change in short-term borrowings	-3,295	712
Acquisition of own shares	-431	-
Own shares used for share options or acquisitions	218	-
Cash inflows/outflows from financing activities	3,746	3,684

Effect of exchange rates on cash and cash equivalents	-66	54
Increase (reduction) in cash and cash equivalents	7,460	1,771

Cash and cash equivalents at beginning of period	7,311	4,375
Cash and cash equivalents at end of period	14,771	6,146

Sep. 30, 2009 Dec. 31, 2008 TEUR TEUR ASSETS Non-current assets Intangible assets 46,269 38,726 Property, plant and equipment 2 7,422 2 3,807 Equity investments - 278 Deferred tax 2,001 1,210 Other assets 1,027 1,118









Total non-current assets 76,719 65,139

Current assets
Cash and cash equivalents 14,771 7,311
Securities 236 332
Trade accounts receivable 18,388 13,985
Inventories 12,532 8,555
Other assets 2,984 2,464
Assets held for disposal - 1,012
Total current assets 48,911 33,659
Total assets 125,630 98,798

EQUITY AND LIABILITIES
Shareholders' equity
Subscibed capital 3,910 3,250
Capital reserves 33,256 30,316
Retained earnings 14,702 10,946
Other reserves -3,736 -3,297
Own shares -787 -359
Equity due to the shareholders of Eckert & Ziegler AG 47,345 40,856
Minority interests 4,264 1,964
Total shareholders' equity 51,609 42,820

Non-current liabilities
Long-term borrowings and finance lease obligations 17,324 10,761
Deferred income from grants and other deferred income 1,458 1,416
Deferred tax 1,660 1,147
Retirement benefit obligations 5,421 420
Other provisions 2 3,815 15,969
Other liabilities 584 529
Total non-current liabilities 50,262 30,242
Current liabilities
Short-term borrowings and finance lease obligations 3,527 7,751
Trade accounts payable 3,823 4,286
Advance payments received 2,202 1,002
Deferred income from grants and other deferred income 374 371
Current tax payable 486 916
Other liabilities 13,347 10,285
Liabilities held for disposal - 1,125
Total current liabilities 2 3,759 2 5,736
Total equity and liabilities 125,630 98,798

Balance December 31, 2008	3,250,000	3,250	30,316	10,946	7	-3,304	-359	40,856	1,964	42,820

Provisions offset by own shares			566					566		566
Purchase of minority interests								0	3,179	3,179
Dividends paid				-786				-786	-104	-890
Total income for the period	0	0	0	4,502	-35	472	0	4,939	-1,465	3,474
Profit of the year				4,502				4,502	-1,465	3,037
Total of expenditures and income directly entered in equity	0	0	0	0	-35	472	0	437	0	437
Reversal of unrealized gains/losses on securities at previous balance sheet date					-42			-42		-42
Unrealized gains/losses on securities at balance sheet date (after tax of EUR 3 thousand)					7			7		7
Foreign currency translation differences						472		472		472
Balance January 1, 2008	3,250,000	3,250 2	9,750	7,230	42	-3,776	-359	36,137	354	36,491
		TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
	Shares	value	reserve	earnings	securities	differences	shares	shareholders	shares	equity
		Nominal	Capital	Retained	gains/losses on	exchange	Own	attributable to	Minotity	holders'
	Subscribed capital				Unrealized	Foreign currency		Equity		share
					Cumulative other equity items					Group

	Cumulative other equity items									Group
	Subscribed capital				Unrealized	Foreign currency		Equity		share
		Nominal	Capital	Retained	gains/losses on	exchange	Own	attributable to	Minotity	holders'
	Shares	value	reserve	earnings	securities	differences	shares	shareholders	shares	equity
		TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
Balance January 1, 2009	3,250,000	3,250	30,316	10,946	7	-3,304	-359	40,856	1,964	42,820
Foreign currency translation differences						-443		-443		-443
Unrealized gains/losses on securities at balance sheet date
(after tax of EUR 5 thousand)					11			11		11
Reversal of unrealized
gains/losses on securities at previous balance sheet date					-7			-7		-7
Total of expenditures and income
directly entered in equity	0	0	0	0	4	-443	0	-439	0	-439
Profit of the year				5,320				5,320 2	,796	8,116
Total income for the period	0	0	0	5,320	4	-443	0	4,881 2	,796	7,677
Dividends paid				-1,132				-1,132	0	-1,132
Purchase and sale of minority interests								0	-496	-496
Application of own shares
for acquisitions and
to service share options	31,650	32	177				4 2	13 2		13
Acquisition or own shares			432	-432			-432	-432		-432
Capital increase	628,633	629 2	,330 2					,959 2		,959
Balance September 30, 2009	3,910,283	3,910	33,256	14,702	11	-3,747	-787	47,345	4,264	51,609

	Nuclear Medicine and Industry		Radio Therapy pharmaceuticals		Other		Elimination		Total
	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008
	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
Sales to external customers	39,631 22	,164 2	3,877	18,916	14,319	10,374	0	0	0	0	77,827	51,454
Sales to other segments	392	191 2	81	1,545 2	9	60	762	1,068	-1,464	-2,864	0	0
Total segmental sales	40,023 22	,355 2	4,158 2	0,461	14,348	10,434	762	1,068	-1,464	-2,864	77,827	51,454
Segment profit
before interest and profit taxes (EBIT)	7,022	5,730	4,485	-3,877	872	-236	-1,549	13,329	-11	-9	10,819	14,937
Interest yield and paid	-416	-312	-464	-305	-749	-726	590	729	11	9	-1,028	-605
Income tax expense	-2,114	-1,746	17	-352 2	5	-1,640 2	99	-1,265			-1,773	-5,003
Profit before minority interests	4,492	3,672	4,038	-4,534	148	-2,602	-660	12,793			8,018	9,329
Special effects before minority interests	0	0	0	-5,011	0	-1,968	0	12,758			0	5,779
Profit before minority interests
without special effects	4,492	3,672	4,038	477	148	-634	-660	35			8,018	3,550

		Nuclear Medicine			Radio-
		and Industry	Therapy		pharmaceuticals			Other		Total
2	01-09 009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008
	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR

Segmental assets	60,593	31,152	45,728	43,903	18,240	16,577	76,997	51,891 2	01,558	143,523
Elimination of inter-segmental shares, equity investments and receivables									-77,928	-58,521
Deferred tax assets 2									,001	8,961
Consolidated total assets									125,631	93,963
Segmental liabilities	-32,924	-13,597	-20,987	-17,308	-20,803	-19,078	-26,743		-5,662 -101,457	-55,645
Elimination of inter-segmental liabilities 2									9,095	17,282
Deferred tax liabilities									-1,660	-2,134
Consolidated liabilities									-74,022	-40,497
Investments	1,052	3,679	1,277	1,263	1,675	750	3 22		4,007	5,714
Depreciations (without non-scheduled depreciations)	-1,695	-743	-1,956	-2,333	-1,469	-1,159	-148	-143	-5,268	-4,378
Non cash income/expenses	-62 2	59	113	1,760	-237	-1,735 2	13	13,336 2	7	13,620

Sales by geographic areas		Jan.–Sep. 2009		Jan.–Sep. 2008
	Million EUR	%	Million EUR	%

Europe	48.3	62	31.3	60
North America	21.0	27	15.2	30
Asia/Pacific	7.8	10	4.0	8
Other	0.7	1	1.0	2
Total	77.8	100	51.5	100

1. General information

These unaudited interim consolidated financial statements as of September 30, 2009 comprise the financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG and its subsidiaries (also referred to hereinafter as "Eckert & Ziegler AG").

2. Accounting and valuation methods

The consolidated financial statements (interim financial statements) of Eckert & Ziegler AG as of September 30, 2009, have been prepared, like the annual financial statements for 2008, in accordance with the International Financial Reporting Standards (IFRS). All of the standards of the London-based International Accounting Standards Board (IASB) which were applicable in the EU on the balance sheet date, as well as the relevant interpretations of the International Financial Reporting Interpretations Committee (IFRIC) and the Standing Interpretations Committee (SIC), have been observed. The accounting and valuation methods described in the appendix to the annual financial statements for 2008 have been applied unchanged. For the preparation of the consolidated financial statements in compliance with the IFRS, it is necessary for estimates and assumptions to be made that impact on the amount and disclosure of recognized asset values and liabilities, income and expenditures. The actual values may differ from the estimates. Significant assumptions and estimates are made concerning useful lives, earnings attainable from goodwill and non-current assets, the realizability of receivables, and the recognition and measurement of provisions. This interim report contains all of the necessary information and adjustments required to produce a picture which reflects the actual circumstances in respect of the assets, financial situation and earnings position of Eckert & Ziegler AG at the time the interim report was produced. The earnings achieved during the course of the current fiscal year do not necessarily allow conclusions to be drawn about the development of future earnings.

3. Companies included in the consolidation

In the consolidated financial statements of Eckert & Ziegler AG, all companies are included where Eckert & Ziegler AG, either indirectly or directly, is able to determine the financial and business policies (control concept).

Company acquisitions and disposals

On January 23, 2009, Eckert & Ziegler AG exercised the purchase option it obtained in December 2008 and purchased all the shares in nuclitec GmbH in Braunschweig, its American subsidiary nuclitec Inc., and the French sister company nuclitec s.a.r.l. The purchase price for the shares amounted to EUR 6,859,000. The ancillary purchase costs amount to EUR 35,000. At the time of publishing this interim financial report, the data gathering required for identifying and evaluating the asset values, debts and potential debts was not yet complete. For this reason, the initial accounting for the acquisition of the company could only be carried out provisionally in accordance with IAS 3.62 at the end of the interim financial statement period.

The acquisition of nuclitec GmbH and its American subsidiary, nuclitec Inc., will be recorded on the balance sheet in this interim financial statement with the following provisional figures:

	Book values	Fair value*
	TEUR	TEUR

Non-current assets	5,636	9,709
Current assets	11,329	11,329
Non-current debts	-14,080	-15,366
Current debts	-4,076	-4,076
Net assets	-1,191	1,596

Acquisition costs		6,158

Goodwill		4,562

* The calculation of the fair values of the assets and debts is not yet completed. Therefore provisional values have been used in accordance with IFRS 3.62.

The acquisition of nuclitec s.a.r.l. will be recorded on the balance sheet in this interim financial statement with the following provisional figures:

	Book values	Fair value*
	TEUR	TEUR

Non-curent assets	2 2
Current assets	1,057	1,057
Non-current debts	-398	-398
Current debts	-287	-287
Net assets	374	374

Acquisition costs		736

Goodwill		362

* The calculation of the fair values of the assets and debts is not yet completed. Therefore provisional values have been used in accordance with IFRS 3.62.

In March 2009, Eckert & Ziegler AG sold its Milan subsidiary Eckert & Ziegler f-con Pharma Italia s.r.l. (FCI) to the Italian company A.C.O.M. – Advanced Center Oncology Macerata SPA. The deconsolidation of FCI resulted in non-cash revenue of EUR 97,000 in the present interim financial statement.

4. Limited comparability of group financial statements with the previous year

In 2008, Eckert & Ziegler AG invested the Therapy segment business in IBt S.A., Seneffe (Belgium) and, in return for this, received 38.5% of the ordinary shares (which equates to 29.9% of the voting shares) in IBt S.A. arising from a capital increase and the loan-related claims. In June 2008, Eckert & Ziegler BEBIG GmbH took over the implants manufacturer Isotron

Isotopentechnik GmbH. In January 2009 the shares of the companies nuclitec GmbH, nuclitec s.a.r.l. and nuclitec Inc. were purchased. In the first quarter of 2009 the shares in Eckert & Ziegler f-con Pharma Italia s.r.l. were sold.

Compared with the first nine months of 2008, this has impacted substantially on the financial situation and earnings position of the Group, which means that it is difficult to compare the Group report with the previous year's report.

5. Currency translation

The financial statements for the companies outside the European Monetary Union are translated based on the concept of functional currency. The following exchange rates were used for the currency translation: See table below

6. Portfolio of own shares

As of September 30, 2009, Eckert & Ziegler AG held 140,916 own shares. This equates to a share of 3.6% of the Company's nominal capital.

7. Substantial transactions with affiliated persons

In respect of the substantial transactions with affiliated persons, we refer to the publications made in the consolidated financial statements dated December 31, 2008.

Country	Currency	Exchange rate on Sep. 30, 2009	Exchange rate on Dec. 31, 2008	Average rate: Jan. 1 - Sep. 30, 2009	Average rate: Jan. 1 - Sep. 30, 2008
USA	USD	1.4592	1.4097	1.3606	1.4398
Czech Rebublic	CZK	25.2204 2	6.6426 2	6.9679 2	4.6554
Great Britain	GBP	0.9166	0.974	0.8872	n.a.
Sweden	SEK	10.2247	10.9861	10.7215	n.a.

8. Events of special significance

Eckert & Ziegler Strahlen- und Medizintechnik AG has been commissioned to produce an innovative cancer medication for the American drug developer Molecular Insight Pharmaceuticals (NASDAQ: MIPI) based in Cambridge, MA. Under the terms of the agreement signed on October 21, 2009, Eckert & Ziegler will set up a new production plant for this purpose over the next few years at its Braunschweig location with financial support from MIPI. The compound Onalta® is a novel radiotherapeutic product candidate under development for the treatment of neuroendocrine tumors. The production plants will be used both for the manufacture of test batches for clinical development and, later, for the manufacture of the approved radiopharmaceuticals.

Berlin, November 3, 2009

Dr. Andreas Eckert Chief Executive Officer

Dr. Edgar Löffler Executive Board Member

Dr. André Heß Executive Board Member

Financial Calendar

November 03, 2009 Quarterly Report III/2009

November 11, 2009 German Equity Forum in Frankfurt

March 30, 2010 Annual Report 2009

March 30, 2010 Balance Press Conference in Berlin

May 04, 2010 Quarterly Report I/2010

May 20, 2010 Annual General Meeting in Berlin

August 03, 2010 Quarterly Report II/2010

November 02, 2010 Quarterly Report III/2010

November 2010 German Equity Forum in Frankfurt

Contact

Eckert & Ziegler Strahlen- und Medizintechnik AG

Karolin Riehle Investor Relations

Robert-Rössle-Str. 10 13125 Berlin www.ezag.com

Telephone+49 (0) 30 94 10 84 - 0 Telefax +49 (0) 30 94 10 84 - 112 E-Mail [email protected]

ISIN DE000565970 ISIN DE000A0L1L69 WKN 565970

AI Terminal